All Products

Show Cart

All Products

Results 1 - 20 of 141

May 2018 TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Mar 2018 Competitor Analysis: CDK9 and Mcl-1 Inhibitors

Mar 2018 Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Jan 2018 Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

Oct 2017 Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

(Discount: 30.00%)

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

Jun 2017 mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Mar 2017 Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Dec 2016 Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

Dec 2016 Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment

Dec 2016 Competitor Analysis: TGF-β Inhibitors for Modulation of the Tumor Microenvironment

Dec 2016 Competitor Analysis: CSF-1R Antagonists for Modulation of the Tumor Microenvironment

Dec 2016 Competitor Analysis: CXCR4 Antagonists for Modulation of the Tumor Microenvironment

Dec 2016 Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology

(Discount: 40.00%)

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

(Discount: 40.00%)

Start
Prev
1
2
3
4
5
6
7
8
Next
End

Currencies

Shopping cart

Cart empty

Latest report

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Featured Products

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Recommended Report

Competitor Analysis: CDK9 and Mcl-1 Inhibitors

Currencies

Shopping cart

Cart empty

Latest report

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Featured Products

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Recommended Report

Competitor Analysis: CDK9 and Mcl-1 Inhibitors

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing